Cargando…

Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021

INTRODUCTION: Vaccination booster shots are completely necessary for controlling breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China. The study aims to estimate effectiveness of booster vaccines for high-risk populations (HRPs). METHODS: A vaccinated Susc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Kangguo, Zhao, Zeyu, Wei, Hongjie, Rui, Jia, Huang, Jiefeng, Guo, Xiaohao, Guo, Yichao, Yang, Shiting, Abudurusuli, Guzainuer, Luo, Li, Liu, Xingchun, Wang, Yao, Xu, Jingwen, Zhu, Yuanzhao, Yang, Meng, Yang, Tianlong, Liu, Weikang, Deng, Bin, Liu, Chan, Li, Zhuoyang, Li, Peihua, Yu, Shanshan, Yang, Zimei, Su, Yanhua, Zhao, Benhua, Niu, Yan, Chen, Tianmu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671839/
https://www.ncbi.nlm.nih.gov/pubmed/34934519
http://dx.doi.org/10.46234/ccdcw2021.259
_version_ 1784615229429121024
author Li, Kangguo
Zhao, Zeyu
Wei, Hongjie
Rui, Jia
Huang, Jiefeng
Guo, Xiaohao
Guo, Yichao
Yang, Shiting
Abudurusuli, Guzainuer
Luo, Li
Liu, Xingchun
Wang, Yao
Xu, Jingwen
Zhu, Yuanzhao
Yang, Meng
Yang, Tianlong
Liu, Weikang
Deng, Bin
Liu, Chan
Li, Zhuoyang
Li, Peihua
Yu, Shanshan
Yang, Zimei
Su, Yanhua
Zhao, Benhua
Niu, Yan
Chen, Tianmu
author_facet Li, Kangguo
Zhao, Zeyu
Wei, Hongjie
Rui, Jia
Huang, Jiefeng
Guo, Xiaohao
Guo, Yichao
Yang, Shiting
Abudurusuli, Guzainuer
Luo, Li
Liu, Xingchun
Wang, Yao
Xu, Jingwen
Zhu, Yuanzhao
Yang, Meng
Yang, Tianlong
Liu, Weikang
Deng, Bin
Liu, Chan
Li, Zhuoyang
Li, Peihua
Yu, Shanshan
Yang, Zimei
Su, Yanhua
Zhao, Benhua
Niu, Yan
Chen, Tianmu
author_sort Li, Kangguo
collection PubMed
description INTRODUCTION: Vaccination booster shots are completely necessary for controlling breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China. The study aims to estimate effectiveness of booster vaccines for high-risk populations (HRPs). METHODS: A vaccinated Susceptible-Exposed-Symptomatic-Asymptomatic-Recovered/Removed (SEIAR) model was developed to simulate scenarios of effective reproduction number (R(eff)) from 4 to 6. Total number of infectious and asymptomatic cases were used to evaluated vaccination effectiveness. RESULTS: Our model showed that we could not prevent outbreaks when covering 80% of HRPs with booster unless R(eff)=4.0 or the booster vaccine had efficacy against infectivity and susceptibility of more than 90%. The results were consistent when the outcome index was confirmed cases or asymptomatic cases. CONCLUSIONS: An ideal coronavirus disease 2019 (COVID-19) booster vaccination strategy for HRPs would be expected to reach the initial goal to control the transmission of the Delta variant in China. Accordingly, the recommendation for the COVID-19 booster vaccine should be implemented in HRPs who are already vaccinated and could prevent transmission to other groups.
format Online
Article
Text
id pubmed-8671839
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-86718392021-12-20 Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021 Li, Kangguo Zhao, Zeyu Wei, Hongjie Rui, Jia Huang, Jiefeng Guo, Xiaohao Guo, Yichao Yang, Shiting Abudurusuli, Guzainuer Luo, Li Liu, Xingchun Wang, Yao Xu, Jingwen Zhu, Yuanzhao Yang, Meng Yang, Tianlong Liu, Weikang Deng, Bin Liu, Chan Li, Zhuoyang Li, Peihua Yu, Shanshan Yang, Zimei Su, Yanhua Zhao, Benhua Niu, Yan Chen, Tianmu China CDC Wkly Methods and Applications INTRODUCTION: Vaccination booster shots are completely necessary for controlling breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China. The study aims to estimate effectiveness of booster vaccines for high-risk populations (HRPs). METHODS: A vaccinated Susceptible-Exposed-Symptomatic-Asymptomatic-Recovered/Removed (SEIAR) model was developed to simulate scenarios of effective reproduction number (R(eff)) from 4 to 6. Total number of infectious and asymptomatic cases were used to evaluated vaccination effectiveness. RESULTS: Our model showed that we could not prevent outbreaks when covering 80% of HRPs with booster unless R(eff)=4.0 or the booster vaccine had efficacy against infectivity and susceptibility of more than 90%. The results were consistent when the outcome index was confirmed cases or asymptomatic cases. CONCLUSIONS: An ideal coronavirus disease 2019 (COVID-19) booster vaccination strategy for HRPs would be expected to reach the initial goal to control the transmission of the Delta variant in China. Accordingly, the recommendation for the COVID-19 booster vaccine should be implemented in HRPs who are already vaccinated and could prevent transmission to other groups. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021-12-03 /pmc/articles/PMC8671839/ /pubmed/34934519 http://dx.doi.org/10.46234/ccdcw2021.259 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Methods and Applications
Li, Kangguo
Zhao, Zeyu
Wei, Hongjie
Rui, Jia
Huang, Jiefeng
Guo, Xiaohao
Guo, Yichao
Yang, Shiting
Abudurusuli, Guzainuer
Luo, Li
Liu, Xingchun
Wang, Yao
Xu, Jingwen
Zhu, Yuanzhao
Yang, Meng
Yang, Tianlong
Liu, Weikang
Deng, Bin
Liu, Chan
Li, Zhuoyang
Li, Peihua
Yu, Shanshan
Yang, Zimei
Su, Yanhua
Zhao, Benhua
Niu, Yan
Chen, Tianmu
Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021
title Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021
title_full Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021
title_fullStr Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021
title_full_unstemmed Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021
title_short Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021
title_sort feasibility of booster vaccination in high-risk populations for controlling coronavirus variants — china, 2021
topic Methods and Applications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671839/
https://www.ncbi.nlm.nih.gov/pubmed/34934519
http://dx.doi.org/10.46234/ccdcw2021.259
work_keys_str_mv AT likangguo feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT zhaozeyu feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT weihongjie feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT ruijia feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT huangjiefeng feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT guoxiaohao feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT guoyichao feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT yangshiting feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT abudurusuliguzainuer feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT luoli feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT liuxingchun feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT wangyao feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT xujingwen feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT zhuyuanzhao feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT yangmeng feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT yangtianlong feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT liuweikang feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT dengbin feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT liuchan feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT lizhuoyang feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT lipeihua feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT yushanshan feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT yangzimei feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT suyanhua feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT zhaobenhua feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT niuyan feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021
AT chentianmu feasibilityofboostervaccinationinhighriskpopulationsforcontrollingcoronavirusvariantschina2021